Octreotide Acetate - NDC Database (Page 4)
80 records found
Page:
67457-239 Apr 25, 2013
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
67457-245 Apr 25, 2013
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
67457-246 Apr 25, 2013
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Mylan Institutional LLC
68083-515 Jun 13, 2023
Octreotide Acetate 200 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
Octreotide Acetate 200 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
68083-516 Jun 13, 2023
Octreotide Acetate 1000 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
Octreotide Acetate 1000 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
68083-517 Jun 22, 2023
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
68083-560 Jun 22, 2023
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Gland Pharma Limited
68462-896 Aug 09, 2023
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Glenmark Pharmaceuticals Inc., USA
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Glenmark Pharmaceuticals Inc., USA
68462-897 Aug 09, 2023
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Glenmark Pharmaceuticals Inc., USA
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Glenmark Pharmaceuticals Inc., USA
71288-566 Feb 28, 2025
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
71288-567 Feb 28, 2025
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
71288-568 Feb 28, 2025
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Meitheal Pharmaceuticals, Inc.
76135-006 Jan 01, 2019
Octreotide Acetate 1000 ug/ml Intravenous Injection by Usv North America Inc.
Octreotide Acetate 1000 ug/ml Intravenous Injection by Usv North America Inc.
76135-009 Feb 01, 2019
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
Octreotide Acetate 50 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
76135-010 Feb 01, 2019
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
Octreotide Acetate 100 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
76135-011 Feb 01, 2019
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
Octreotide Acetate 500 ug/ml Intravenous; Subcutaneous Injection, Solution by Usv North America Inc.
Page:
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.